// App-Quantinova.ai

TCT-181 : Safety and Efficacy of a Novel Abluminal Groove-Filled Biodegradable Polymer Sirolimus-Eluting Stent for the Treatment of De Novo Coronary Lesions: 12-Month Results from the Prospectively Patient-Level Pooled Analysis of the TARGET I and TARGET II Trials

Researchers

Presenter

  • Run-Lin Gao

Principal Investigators

  • Bo Xu

  • Alexandra Lansky

  • Wei Li

  • Yelin Zhao

  • Martin Leon

  • Yuejin Yang

  • Ruiyan Zhang

  • Ma Changsheng

  • Hui Li

  • Shao Liang Chen

  • Yaling Han

  • Zuyi Yuan

  • Yong Huo

Medical Centers

  • Peking University People's Hospital, Beijing, China

  • Affilaited Anzhen Hospital of Capital Medical University, Beijing, China

  • Daqing Oil Field General Hospital, Daqing, China

  • Nanjing First Hospital, Nanjing Medical University, Nanjing, China

  • Columbia University / Cardiovascular Research Foundation, New York, NY

  • Shenyang Northern Hospital, Shenyang, AK

  • Fu Wai Hospital, National Center for Cardiovascular Diseases, China, Beijing, China

  • National Center for Cardiovascular Diseases of China, Beijing, China

  • The First Affiliated Hospital of Xi?an Jiaotong University School of Medicine, Xian, China

  • Xin Hua Hospital to Shanghai Jiao Tong University School of Medicine, Shanghai, China

  • Yale University School of Medicine, New Haven, United States

Locations

  • United States

  • China

Companies

  • N/A

Study Components

Therapeutic Area

  • Endocrine/metabolic Diseases (ME)

Disease

  • Myocardial infarction

  • Diabetes

  • Venous thrombosis

  • Coronary Artery Disease

Biomarkers

  • N/A

Drug/Treatment

  • sirolimus

  • Everolimus

  • Rapacan

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved